Table 6 Prognostic factors for overall survival

Sex (ref: Male)

0.0002

0.801 (0.713–0.899)

0.0003

0.792 (0.698–0.900)

Age (ref: < 75 years old)

0.0024

1.389 (1.123–1.717)

–

–

 LMS

0.0004

0.765 (0.659–0.888)

0.0010

0.765 (0.652–0.897)

 DLPS

0.0269

1.291 (1.030–1.619)

0.2034

1.171 (0.918–1.492)

 MPNST

0.1368

1.273 (0.926–1.751)

0.2183

1.234 (0.883–1.726)

 SS

0.4738

1.074 (0.883–1.307)

0.0764

1.206 (0.980–1.485)

 UPS

0.0061

1.347 (1.089–1.668)

0.1839

1.168 (0.929–1.469)

 Grade (ref: < 3)

< 0.0001

1.692 (1.491–1.920)

< 0.0001

1.687 (1.483–1.919)

 Number of metastatic sites (ref: 1)

0.0136

1.200 (1.038–1.387)

0.0009

1.305 (1.115–1.528)

 Liver metastasis (ref: no)

0.1056

0.891 (0.774–1.025)

–

–

 Locoregional treatment (ref: no)

< 0.0001

0.412 (0.365–0.465)

< 0.0001

0.400 (0.351–0.455)

 Clinical trial (ref: no)

< 0.0001

0.750 (0.653–0.862)

0.0002

0.755 (0.651–0.877)

 Off-label drugs (ref: no)

< 0.0001

0.791 (0.703–0.890)

–

–

 Anthracycline (ref: no)

0.0046

0.838 (0.741–0.947)

–

–

 Anthracycline in first line (ref: no)

0.0127

0.861 (0.765–0.968)

–

–

 Polychemotherapy in first line (ref: no)

0.0003

0.804 (0.715–0.902)

0.0023

0.822 (0.724–0.932)